Your browser doesn't support javascript.
loading
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa, Shinji; Yamamoto, Norio; Hayashi, Katsuhiro; Takeuchi, Akihiko; Igarashi, Kentaro; Tsuchiya, Hiroyuki.
Afiliação
  • Miwa S; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
  • Yamamoto N; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
  • Hayashi K; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
  • Takeuchi A; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
  • Igarashi K; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
  • Tsuchiya H; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Int J Mol Sci ; 23(3)2022 Jan 20.
Article em En | MEDLINE | ID: mdl-35163019
ABSTRACT
Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Condrossarcoma / Colágeno Tipo II / Isocitrato Desidrogenase / Mutação / Antineoplásicos Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Condrossarcoma / Colágeno Tipo II / Isocitrato Desidrogenase / Mutação / Antineoplásicos Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão